Related Experiment Video
Updated: Feb 25, 2026
07:51
Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
1.2K
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis
Steven D Nathan1, Fernando J Martinez
1aAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VirginiabDivision of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York City, New York, USA.
Current Opinion in Pulmonary Medicine
|August 4, 2017
Summary
New therapies like nintedanib and pirfenidone offer hope for idiopathic pulmonary fibrosis (IPF) management. While not cures, these treatments show IPF can be modulated, guiding future clinical trial designs.
Area of Science:
- Pulmonology
- Fibrotic lung diseases
- Clinical trial design
Background:
- Idiopathic pulmonary fibrosis (IPF) remains a significant clinical challenge.
- Nintedanib and pirfenidone represent advancements in IPF therapeutics, demonstrating disease modulation.
- Despite new treatments, IPF is not curable and remains a fatal condition.
Purpose of the Study:
- To review the evolution of idiopathic pulmonary fibrosis (IPF) management and clinical trial design.
- To synthesize lessons learned from past and present IPF clinical trials.
- To inform the development of more efficient and successful future clinical trial designs for IPF.
Main Methods:
- Review of existing literature on IPF natural history.
- Analysis of clinical development programs for nintedanib and pirfenidone.
- Examination of numerous negative clinical trials preceding current therapies.
Main Results:
- The advent of nintedanib and pirfenidone marks a new era in IPF treatment.
- Therapeutic interventions can modulate IPF, though not provide a cure.
- Past clinical trials have yielded crucial insights into IPF natural history and trial design.
Conclusions:
- Lessons from IPF trials inform future research directions.
- Optimized clinical trial designs are essential for advancing IPF therapies.
- Continued research is vital to overcome the challenges of IPF and improve patient outcomes.
More Related Videos
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
546
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546
01:20COPD: Pathogenesis and Clinical Features
2.0K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.0K
01:28Preclinical Development: Overview
6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.9K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
52
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
52
01:26Drug Discovery: Overview
12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K